CORT
Price
$35.80
Change
-$1.23 (-3.32%)
Updated
Jan 15, 11:19 AM (EDT)
Capitalization
3.9B
34 days until earnings call
Intraday BUY SELL Signals
DNLI
Price
$18.40
Change
+$0.13 (+0.71%)
Updated
Jan 15, 11:22 AM (EDT)
Capitalization
2.85B
46 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CORT vs DNLI

Header iconCORT vs DNLI Comparison
Open Charts CORT vs DNLIBanner chart's image
Corcept Therapeutics
Price$35.80
Change-$1.23 (-3.32%)
Volume$575
Capitalization3.9B
Denali Therapeutics
Price$18.40
Change+$0.13 (+0.71%)
Volume$200
Capitalization2.85B
CORT vs DNLI Comparison Chart in %
View a ticker or compare two or three
VS
CORT vs. DNLI commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CORT is a Hold and DNLI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (CORT: $37.04 vs. DNLI: $18.27)
Brand notoriety: CORT and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CORT: 76% vs. DNLI: 72%
Market capitalization -- CORT: $3.9B vs. DNLI: $2.85B
CORT [@Biotechnology] is valued at $3.9B. DNLI’s [@Biotechnology] market capitalization is $2.85B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CORT’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • CORT’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, CORT is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CORT’s TA Score shows that 5 TA indicator(s) are bullish while DNLI’s TA Score has 4 bullish TA indicator(s).

  • CORT’s TA Score: 5 bullish, 5 bearish.
  • DNLI’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CORT is a better buy in the short-term than DNLI.

Price Growth

CORT (@Biotechnology) experienced а +0.11% price change this week, while DNLI (@Biotechnology) price change was +7.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.31%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was +43.69%.

Reported Earning Dates

CORT is expected to report earnings on Feb 18, 2026.

DNLI is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (+0.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CORT($3.9B) has a higher market cap than DNLI($2.85B). DNLI YTD gains are higher at: 10.660 vs. CORT (6.437). CORT has higher annual earnings (EBITDA): 67.4M vs. DNLI (-534.17M). DNLI has more cash in the bank: 848M vs. CORT (422M). CORT has less debt than DNLI: CORT (6.36M) vs DNLI (44.4M). CORT has higher revenues than DNLI: CORT (741M) vs DNLI (0).
CORTDNLICORT / DNLI
Capitalization3.9B2.85B137%
EBITDA67.4M-534.17M-13%
Gain YTD6.43710.66060%
P/E Ratio42.59N/A-
Revenue741M0-
Total Cash422M848M50%
Total Debt6.36M44.4M14%
FUNDAMENTALS RATINGS
CORT vs DNLI: Fundamental Ratings
CORT
DNLI
OUTLOOK RATING
1..100
8314
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
88100
SMR RATING
1..100
5197
PRICE GROWTH RATING
1..100
9650
P/E GROWTH RATING
1..100
4899
SEASONALITY SCORE
1..100
4950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CORT's Valuation (82) in the Pharmaceuticals Other industry is in the same range as DNLI (93) in the Biotechnology industry. This means that CORT’s stock grew similarly to DNLI’s over the last 12 months.

CORT's Profit vs Risk Rating (88) in the Pharmaceuticals Other industry is in the same range as DNLI (100) in the Biotechnology industry. This means that CORT’s stock grew similarly to DNLI’s over the last 12 months.

CORT's SMR Rating (51) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (97) in the Biotechnology industry. This means that CORT’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's Price Growth Rating (50) in the Biotechnology industry is somewhat better than the same rating for CORT (96) in the Pharmaceuticals Other industry. This means that DNLI’s stock grew somewhat faster than CORT’s over the last 12 months.

CORT's P/E Growth Rating (48) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (99) in the Biotechnology industry. This means that CORT’s stock grew somewhat faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CORTDNLI
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
65%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
63%
Bullish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 1 day ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
66%
Bearish Trend 11 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CORT
Daily Signal:
Gain/Loss:
DNLI
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYMCX8.580.07
+0.82%
Royce Micro-Cap Consult
JTUAX18.770.12
+0.64%
JPMorgan US Small Company A
TSCGX19.42-0.02
-0.10%
Thrivent Small Cap Growth S
ETTGX133.07-0.99
-0.74%
Eaton Vance Tx-Mgd Growth 1.1 A
JGRJX37.38-0.51
-1.35%
JPMorgan Growth Advantage R2

CORT and

Correlation & Price change

A.I.dvisor indicates that over the last year, CORT has been loosely correlated with VTVT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CORT jumps, then VTVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CORT
1D Price
Change %
CORT100%
+1.90%
VTVT - CORT
49%
Loosely correlated
+7.21%
TENX - CORT
41%
Loosely correlated
+21.40%
AGIO - CORT
41%
Loosely correlated
+3.35%
DNLI - CORT
40%
Loosely correlated
+0.88%
ARCT - CORT
37%
Loosely correlated
+2.11%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RGNX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+0.88%
RGNX - DNLI
54%
Loosely correlated
-0.66%
BEAM - DNLI
53%
Loosely correlated
+2.49%
VIR - DNLI
53%
Loosely correlated
+8.08%
SYRE - DNLI
52%
Loosely correlated
+5.17%
CDXS - DNLI
51%
Loosely correlated
+4.09%
More